Neuland Labs soared 15% to new highs on strong Q1 results and a breakout above key resistance. Analyst Vijay Gupta flagged momentum backed by CMS growth, peptide contracts, and rising FII interest. With bullish technicals and volume, he sees upside toward ₹15,500-16,000. Support lies at ₹12,700. Sector rerating and operational tailwinds make Neuland attractive for growth investors.